GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Biosciences Inc (NAS:CBIO) » Definitions » Cash-to-Debt

Catalyst Biosciences (Catalyst Biosciences) Cash-to-Debt : No Debt (1) (As of Sep. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Catalyst Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Catalyst Biosciences's cash to debt ratio for the quarter that ended in Sep. 2023 was No Debt (1).

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Catalyst Biosciences could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Catalyst Biosciences's Cash-to-Debt or its related term are showing as below:

CBIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.66   Med: 56.92   Max: No Debt
Current: 58

During the past 13 years, Catalyst Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.66. And the median was 56.92.

CBIO's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.5 vs CBIO: 58.00

Catalyst Biosciences Cash-to-Debt Historical Data

The historical data trend for Catalyst Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Catalyst Biosciences Cash-to-Debt Chart

Catalyst Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt 42.66 48.27 19.64 570.16

Catalyst Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.60 570.16 No Debt No Debt No Debt

Competitive Comparison of Catalyst Biosciences's Cash-to-Debt

For the Biotechnology subindustry, Catalyst Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Catalyst Biosciences's Cash-to-Debt falls into.



Catalyst Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Catalyst Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Catalyst Biosciences's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Catalyst Biosciences had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Catalyst Biosciences  (NAS:CBIO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Catalyst Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Catalyst Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Biosciences (Catalyst Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 710, South San Francisco, CA, USA, 94080
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.
Executives
Han Ying director 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Charles C Wu director, officer: Chief Executive Officer 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Songjiang Ma director, officer: President 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Weiguo Ye officer: Chief Operating Officer 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Renate Parry director 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Ruoyu Chen officer: Interim CFO 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Gordon Carmichael director 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Gni Usa, Inc. 10 percent owner 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Augustine Lawlor director 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Andrea Hunt director 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Seline E. Miller officer: SVP Finance; Interim CFO & PAO C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Gni Hong Kong Ltd 10 percent owner 12/F ELITE CENTRE, 22 HUNG TO ROAD, KWUN TONG KL K3 0000
Gni Group Ltd. 10 percent owner NIHONBASHI-HONCHO YS BLDG 3F, 2-2-2 NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-0023
Thomas Wilson Eastling director 17520 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Ying Luo director NIHONBASHI-HONCHO YS BLDG 3F, 2-2-2 NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-0023